Aviva Systems Biology
Aviva Systems Biology is a privately held San Diego-based life science reagent company founded in 2002 that sells antibodies, recombinant proteins, ELISA kits, peptides, and Western blot reagents to academic researchers, pharmaceutical/biotech firms, and diagnostic manufacturers globally through catalog and custom services.
- Company typePrivate
- Founded2002
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aviva Systems Biology does
Aviva Systems Biology is a privately held life science reagent company founded in 2002 and headquartered in San Diego, California, that manufactures and distributes antibodies, recombinant proteins, ELISA kits, peptides, and Western blot reagents to the global research community. The company operates one of the broader catalogs in the research-reagent segment, with nearly 500,000 SKUs spanning 20,000+ validated ELISA kits, 20,000+ polyclonal antibodies, and 2,500+ recombinant proteins produced via proprietary E. coli, mammalian, and yeast expression systems. Its technology stack includes the Carterra LSA high-throughput SPR platform for kinetic antibody screening (up to 1,152 monoclonal antibodies in parallel), proprietary ASB® Fluor conjugation chemistry for direct-labeled IHC/IF applications, and Chicken IgY antibody development capability. Through its wholly-owned subsidiary Genway Biotech, Aviva maintains ISO 13485 accreditation enabling custom manufacturing for FDA-regulated and CE-mark in vitro diagnostic products.
The company serves three primary customer segments: academic and research institutions (its largest base), pharmaceutical and biotech companies (custom antibody development, recombinant protein production, ELISA development), and diagnostic manufacturers (regulated ISO 13485/CMO services). Revenue is generated through one-time catalog product sales priced at $115-$949 per unit, custom services engagements priced on a project basis, and a custom conjugation service at $100 per reaction. Distribution runs through a direct e-commerce storefront, a global distributor network, and event-driven scientific conference engagement (AACR, AAIC, AbVal). The company is led by President Kevin Harvey, PhD, with founder Julian Yuan also identified in leadership.
Recent strategic activity in 2025 includes product launches targeting neurodegenerative disease biomarkers (Tau ELISA Kits, Progranulin ELISA Kit) and new ECL substrate formulations, alongside first-time presence at AAIC signaling neuroscience vertical expansion. Aviva is wholly founder/principal-owned with no disclosed external funding rounds and operates within an 11-50 employee band.
Aviva Systems Biology firmographics
Firmographics- Name
- Aviva Systems Biology
- Legal name
- Aviva Systems Biology Corporation
- Website
- https://avivasysbio.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Aviva Systems Biology is a privately held San Diego-based life science reagent company founded in 2002 that sells antibodies, recombinant proteins, ELISA kits, peptides, and Western blot reagents to academic researchers, pharmaceutical/biotech firms, and diagnostic manufacturers globally through catalog and custom services.
- Ownership category
- akta.pro rank
Aviva Systems Biology industry classification
Industry- Product category
- Life Science Research Reagents
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industries
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Aviva Systems Biology is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aviva Systems Biology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Research Products Sales: Sale of catalog products including antibodies (polyclonal, monoclonal, recombinant), ELISA kits, recombinant proteins, peptides, and Western blot reagents. Products sold directly through e-commerce website with pricing ranging from $115 to $949+ per unit.
- Custom Services: Custom antibody development, recombinant protein production, ELISA development, and high-throughput antibody characterization services. Includes ISO 13485/CMO services for regulated products.
- Conjugation Services: Antibody conjugation services for labeling with various fluorophores, biotin, and HRP for $100 per conjugation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Tau ELISA Kits - Total and Phospho-Tau assays |
| Unit Pricing | Pay-as-you-go | Progranulin ELISA Kit |
| Unit Pricing | Pay-as-you-go | Recombinant Monoclonal Antibodies |
| Unit Pricing | Pay-as-you-go | Polyclonal Antibodies |
| Unit Pricing | Pay-as-you-go | HRP-conjugated Secondary Antibodies |
| Unit Pricing | Pay-as-you-go | Epitope Tag Antibodies |
| Unit Pricing | Pay-as-you-go | Peptides |
| Unit Pricing | Pay-as-you-go | Custom Conjugation Services |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Aviva Systems Biology product offering
Product offeringCore offering
Aviva Systems Biology manufactures and sells a catalog of approximately 500,000 life science research products — primarily polyclonal and monoclonal antibodies, recombinant monoclonal antibodies, ELISA kits, recombinant proteins, peptides, and Western blot reagents — alongside custom antibody production, recombinant protein expression, antibody conjugation, ELISA development, and ISO 13485-accredited contract manufacturing services for the research, drug discovery, and diagnostic communities.
Product overview
Aviva Systems Biology is a life science company offering a comprehensive portfolio of antibody-based research products and custom services. The product portfolio includes over 20,000 ELISA Kits, Polyclonal Antibodies, Monoclonal Antibodies, Recombinant Monoclonal Antibodies, Secondary Antibodies, Recombinant Proteins, Peptides, Western Blot Reagents (AvivaBlot™ ECL Substrates), Epitope Tag Antibodies, and Sample Preparation Reagents. Custom services encompass High Throughput Antibody Characterization (SPR-based), Custom Antibody Production (Chicken IgY, Rabbit IgG, Phospho-Specific, Recombinant mAb), Custom Recombinant Protein Production (E. coli, Mammalian, Yeast), ELISA Development, Custom Conjugation, and ISO 13485/CMO Services for regulated diagnostics. Research areas span Cancer, Cardiovascular, Cell Biology, Developmental Biology, Epigenetics, Immunology, Infectious Disease, Metabolism, Neuroscience, Organelle Markers, Signaling Pathways, and Veterinary Sciences.
Differentiator
Problem solved
Functional benefit
Brands
- Genway Biotech: ISO 13485/GMP compliant subsidiary for development, validation, and production of antibodies and proteins.
- ASB Flours
- AvivaBlot
- Protein on Demand
Products and services
- ELISA Kits Over 20,000 validated ELISA kits for detecting proteins and biomarkers across multiple species, including high-sensitivity and chemiluminescent formats. Sold to academic, biotech, pharma, and diagnostic manufacturer customers.
- Polyclonal Antibodies
Quantifiable outcome
- Successfully produced over 2,500 recombinant proteins
- +2 more outcomes
Companies that use Aviva Systems Biology
Customer profileSegments3 records
Ideal customer profiles3 records
Aviva Systems Biology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Aviva Systems Biology partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CarterracoreAviva Systems Biology uses Carterra LSA (Label-free SPR Array) technology for high-throughput antibody characterization services. The partnership enables kinetically screening up to 1,152 mAbs and 384 clones simultaneously, with <200µL sample usage per interactant. Carterra's technology supports Aviva's antibody validation and characterization services.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Aviva Systems Biology competitors and assessment
Company assessmentDirect peers
- Novus Biologicals (Bio-Techne): Antibody, ELISA kit, and recombinant protein supplier now under Bio-Techne, serving academic and pharma researchers across similar research areas. Directly comparable catalog structure with the backing of a much larger parent.
- Proteintech: Antibody manufacturer known for proprietary antibodies with strong validation data, serving academic and biotech researchers. Closely comparable product positioning, with emphasis on validation rigor similar to Aviva's Enhanced Validation program.
- Abcam: One of the largest antibody reagent suppliers globally (now part of Danaher), offering polyclonal, monoclonal, and recombinant antibodies plus ELISA kits. Directly comparable to Aviva's catalog model with much larger scale and broader geographic reach.
- Cell Signaling Technology: Leading US-based antibody and ELISA kit supplier focused on signaling pathway and cancer/neuroscience research. Closely comparable catalog, validation rigor, and customer base to Aviva's premium research offering.
- Rockland Immunochemicals: Privately held US antibody and immunoassay reagent manufacturer with custom antibody and conjugation services. Comparable mid-sized private competitor with similar catalog + custom service mix.
- GenScript: Global biotech offering custom antibody and recombinant protein services plus catalog reagents, serving pharma/biotech/academic customers. Comparable custom services and catalog overlap with Aviva's Protein on Demand and custom antibody offerings.
- Santa Cruz Biotechnology: Long-established broad-portfolio antibody and reagent supplier targeting academic and biotech researchers. Closely matches Aviva's polyclonal/monoclonal breadth and catalog-led distribution model.
Broad incumbents
- Thermo Fisher Scientific (Life Sciences): Largest life science tools provider offering Invitrogen and Thermo Scientific branded antibodies, ELISA kits, and proteins across all major research areas. Represents the dominant broad incumbent Aviva competes against for institutional accounts.
- Merck Millipore Sigma: Major life science reagent supplier providing antibodies, ELISA kits, proteins, and peptides as part of Merck's broader life science portfolio. Overlaps with Aviva's catalog across most product categories with significantly greater scale and distribution.
- Bio-Rad Laboratories: Large life science tools company offering antibodies, ELISA kits, and recombinant proteins as part of a wider portfolio spanning instruments and clinical diagnostics. Overlaps with Aviva's catalog but at significantly larger scale and broader scope.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Aviva Systems Biology social profiles
Digital presenceAviva Systems Biology compliance and trust
Trust signalCompliance1 record
Aviva Systems Biology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aviva Systems Biology leadership team
Management profileNumber of profiles
Profiles2 records
Aviva Systems Biology subsidiaries and ownership
Company hierarchySubsidiaries1 record
Aviva Systems Biology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aviva Systems Biology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aviva Systems Biology
What does Aviva Systems Biology do?
Aviva Systems Biology manufactures and sells a catalog of approximately 500,000 life science research products — primarily polyclonal and monoclonal antibodies, recombinant monoclonal antibodies, ELISA kits, recombinant proteins, peptides, and Western blot reagents — alongside custom antibody production, recombinant protein expression, antibody conjugation, ELISA development, and ISO 13485-accredited contract manufacturing services for the research, drug discovery, and diagnostic communities.
When was Aviva Systems Biology founded?
Aviva Systems Biology was founded in 2002. It employs 11 to 50 people.
Where is Aviva Systems Biology based?
Aviva Systems Biology is headquartered in San Diego, United States, in the North America region.
How does Aviva Systems Biology make money?
Three revenue lines are on record. Research Products Sales are the primary driver. The others are custom Services and conjugation Services.
Who are Aviva Systems Biology's main competitors?
Direct peers on record are Novus Biologicals (Bio-Techne), Proteintech, Abcam, Cell Signaling Technology, Rockland Immunochemicals, GenScript and Santa Cruz Biotechnology. Broad incumbents are Thermo Fisher Scientific (Life Sciences), Merck Millipore Sigma and Bio-Rad Laboratories.
Does Aviva Systems Biology have an API?
No public API is recorded for Aviva Systems Biology.
What industry is Aviva Systems Biology in?
Aviva Systems Biology's product category is Life Science Research Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.